Press Releases on September 17, 2018 - EIN Presswire - Press Release Distribution Service

Published on September 17, 2018 - 12:05 GMT

Human medicines European public assessment report (EPAR): Qtern, saxagliptin,dapagliflozin, Diabetes Mellitus, Type 2;Diabetes ...

Dapagliflozin in combination with saxagliptin (the same combination as in Qtern) was evaluated in 3 main studies involving 1,169 adults with type 2 diabetes. The main measure of effectiveness was the change after 24 weeks of treatment in the level of a …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:05 GMT

Human medicines European public assessment report (EPAR): Qtern, saxagliptin,dapagliflozin, Diabetes Mellitus, Type 2;Diabetes ...

Dapagliflozin in combination with saxagliptin (the same combination as in Qtern) was evaluated in 3 main studies involving 1,169 adults with type 2 diabetes. The main measure of effectiveness was the change after 24 weeks of treatment in the level of a …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:05 GMT

Human medicines European public assessment report (EPAR): Myfenax, mycophenolate mofetil, Graft Rejection, Date of authorisation: ...

Myfenax treatment should be initiated and maintained by a qualified transplant specialist. The way that Myfenax should be given and the dose depend on the type of organ transplant and the patient’s age and size. For kidney transplants, the recommended dose …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:05 GMT

Human medicines European public assessment report (EPAR): Myfenax, mycophenolate mofetil, Graft Rejection, Date of authorisation: ...

Myfenax treatment should be initiated and maintained by a qualified transplant specialist. The way that Myfenax should be given and the dose depend on the type of organ transplant and the patient’s age and size. For kidney transplants, the recommended dose …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:05 GMT

Human medicines European public assessment report (EPAR): Glyxambi, empagliflozin,linagliptin, Diabetes Mellitus, Type 2, Date of ...

Empagliflozin in combination with linagliptin (the same combination as in Glyxambi) was evaluated in 3 main studies involving 1,221 adults with type 2 diabetes. The main measure of effectiveness was the change after 24 weeks of treatment in the level of a …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:05 GMT

Human medicines European public assessment report (EPAR): Glyxambi, empagliflozin,linagliptin, Diabetes Mellitus, Type 2, Date of ...

Empagliflozin in combination with linagliptin (the same combination as in Glyxambi) was evaluated in 3 main studies involving 1,221 adults with type 2 diabetes. The main measure of effectiveness was the change after 24 weeks of treatment in the level of a …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:05 GMT

Bearing Announces Submission of the Environmental Impact Assessment ("EIA")

The Maricunga Lithium Project (the “Maricunga Project”) achieves a major milestone by submitting the project Environmental Impact Assessment (“EIA”) to the Chilean Environmental Authority, SEA ("Servicio de Evaluación Ambiental"), after more than …

Distribution channels: Chemical Industry

Published on September 17, 2018 - 12:05 GMT

Human medicines European public assessment report (EPAR): Plegridy, peginterferon beta-1a, Multiple Sclerosis, Date of ...

Plegridy is a medicine used to treat multiple sclerosis (MS), a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves. It is used specifically in adults with a type of MS known as …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:05 GMT

Human medicines European public assessment report (EPAR): Plegridy, peginterferon beta-1a, Multiple Sclerosis, Date of ...

Plegridy is a medicine used to treat multiple sclerosis (MS), a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves. It is used specifically in adults with a type of MS known as …

Distribution channels: Healthcare & Pharmaceuticals Industry